• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Article

Phase III under way

New York - Adjuvant therapy with a macrophage-activating growth factor appears to prolong survival in high-risk melanoma, Lynn E. Spitler, M.D., said.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!
Related Videos
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
Related Content
Daily Derm Times: July 9, 2025
July 10th 2025

Daily Derm Times: July 9, 2025

Derm Dispatch: Advocating for Skin and Nail Health to Spread Melanoma Awareness
May 23rd 2025

Derm Dispatch: Advocating for Skin and Nail Health to Spread Melanoma Awareness

Q&A: Bridging the Gap in Dermatologic Care with a Provider-First Digital Solution
July 9th 2025

Q&A: Bridging the Gap in Dermatologic Care with a Provider-First Digital Solution

Derm Dispatch: Discussing Early Detection and Education With a Melanoma Survivor
May 20th 2025

Derm Dispatch: Discussing Early Detection and Education With a Melanoma Survivor

Optimal Targets Linked to Better AD Outcomes
July 9th 2025

Optimal Targets Linked to Better AD Outcomes

Navigating Changes in Dermatology and Clinical Research Efforts
July 9th 2025

Navigating Changes in Dermatology and Clinical Research Efforts

© 2025 MJH Life Sciences

All rights reserved.